Chapter 143 Copper Chelator Therapy

  1. Allen KG, Twedt DC, Hunsaker HA: Tetramine cupruretic agents: a comparison in dogs, Am J Vet Res 48(1):28-30, 1987. PUBMED Abstract
  2. Center SA: Pathophysiology of liver disease: normal and abnormal function. In Guilford WG, Strombeck DR, editors: Strombeck's small animal gastroenterology, ed 3, Philadelphia, 1996, Saunders, p 597.
  3. Hoffmann G: Copper associated liver diseases, Vet Clin North Am Small Anim Pract 39:489, 2009.
  4. Rothuizen J: General principles in the treatment of liver disease. In Ettinger SJ, Feldman EC, editors: Textbook of veterinary internal medicine, ed 7, Philadelphia, 2010, Saunders, p 1629.
  5. Scherk MA, Center SA: Toxic, metabolic, infectious, and neoplastic liver disease. In Ettinger SJ, Feldman EC, editors: Textbook of veterinary internal medicine, ed 7, Philadelphia, 2010, Saunders, p 1679.
  6. Spee B, Arends B, van den Ingh T: Copper metabolism and oxidative stress in chronic inflammatory and cholestatic liver diseases in dogs, J Vet Intern Med 20:1085, 2006. PUBMED Abstract
  7. Twedt DC, Hunsaker MS, Allen KGD: Use of 2,3,2-tetramine as a hepatic copper chelating agent for treatment of copper hepatotoxicosis in Bedlington terriers, J Am Vet Med Assoc 192:52, 1988. PUBMED Abstract
  8. Wiggelinkhuizen M et al: Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease, Aliment Pharmacol Ther 29:947, 2009. PUBMED Abstract